Scilex Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.scilexpharma.com
Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ZTlido (Lidocaine Topical System) 1.8%Drug: Aspercreme (Lidocaine Patch 4%)Drug: IcyHot (Lidocaine 4% + Menthol 1% Patch)Drug: Salonpas (Lidocaine Patch 4%)
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05106400
- Locations
- 🇺🇸
AXIS Clinicals, Dilworth, Minnesota, United States
Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain
Phase 2
Completed
- Conditions
- Moderate to Severe Acute Lower Back Pain
- Interventions
- Drug: SP-103Drug: Placebo
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05096494
- Locations
- 🇺🇸
Chicago Anaesthesia Research Specialists, Chicago, Illinois, United States
🇺🇸Horizon Clinical Research, Newnan, Georgia, United States
🇺🇸Costal Clinical Research Specialists, Jacksonville, Florida, United States
Pharmacokinetics of SP-104
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SP-104Drug: Naltrexone Hydrochloride 50Mg Oral Tablet
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05002946
- Locations
- 🇳🇿
Christchurch Clinical Studies Trust (NZCR), Christchurch, New Zealand
Study to Evaluate the Safety of SP-104
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: SP-104Drug: Naltrexone immediate release oral capsules
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04958876
- Locations
- 🇳🇿
Auckland Clinical Studies (NZCR), Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust (NZCR), Christchurch, New Zealand
Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04819581
- Locations
- 🇺🇸
AXIS Clinicals, Dilworth, Minnesota, United States
Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04784728
- Locations
- 🇺🇸
AXIS Clinicals, Dilworth, Minnesota, United States
Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04319926
- Locations
- 🇺🇸
AXIS Clinicals, Dilworth, Minnesota, United States
Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04320173
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
Adhesion of Lidocaine Topical System 1.8%
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT04312750
Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and Exercise
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Scilex Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04150536
© Copyright 2025. All Rights Reserved by MedPath